
Medication Monitoring In Primary Care: Insights for Non-Medical Prescribers

Dr Ahmed Ameer PhD

Pharmacist
Ahmed.Ameer@nhs.net
May 2022

Agenda

- What is medicine/drug monitoring?
- Implication
- Examples of drug monitoring
- Tips for NMP




Drug monitoring

- Typically refers to the measurement of drug concentration in body fluids
- Medicine safety to ensure patient is benefiting from the medication use with minimal harm caused
- Patient is not developing a medicine related problem
- Review of benefit vs risk
- Polypharmacy on the increase

Implication

- Patients
 - Benefit vs risk of harm
- Individual NMP
 - Prescribing competently
- Organisation
 - Litigation
 - Regulation

Medication safety in the NHS



97% of medication errors reported to the NHS result in no or low patient harm

ACE-I & ARB

- BP and U&E
- HF \rightarrow 6 monthly
- BP \rightarrow 12 monthly
- Watch out for:
 - Low sodium (<132 mmol/L)
 - High Potassium (>5 mmol/L

Creatinine increase between 20-30%; eGFR decrease more than 15%

• Remeasure renal function within 2 weeks

Creatinine increase between 30-50%; level greater than 200micromol/L; eGFR less than 30ml/min/1.73m²

- · Review volume status
- · Reduce dose temporarily
- Stop diuretic (if applicable)
- Stop ACEI/ARB

Creatinine increase between 50-100%; level greater than 256micromol/L; eGFR between 20-25ml/min/1.73m²

- Reduce dose
- Stop diuretic (if applicable)
- Stop ACE/ARB
- · Consider specialist referral

Creatinine increase greater than 100%; level greater than 310micromol/L; eGFR greater than 20ml/min/1.73m²

Anticoagulants

- Warfarin
 - INR \rightarrow 2 to 3 monthly
- DOAC
 - FBC & LFT →3 monthly
 - U&E \rightarrow 6 monthly
 - Weight
 - CrCl
 - Indication-CrCl based dosing

Amiodarone

- TFT, LFT & U&E →6 monthly
- Chest x-ray, eye assessment & ECG → 12 monthly

Antidiabetic Agents

- HbA1C, FBC, LFT & U&E \rightarrow 3. 6 or 12 monthly
- BMI, urine ACR, Bone profile & vitamin B12 → 12 monthly

Antipsychotics

- HbA1C, FBC, lipids profile, LFT & U&E → 12 monthly
- BMI, BP & ECG → 12 monthly

Lithium

- Lithium level → 3 or 6 monthly
- HbA1C, FBC, lipids profile, LFT, TFT, Ca^{2+l} U&E & weight → 6 monthly

Azathioprine, Methotrexate & Sulfalazine


- FBC & LFT →3 monthly
- U&E \rightarrow 6 monthly

LABORATORY EVENTS	VALUES	ACTION
MCV	> 110 fl	Check B12 and folate – supplementation may be required if low. Also check TSH. If these are all normal, seek Specialist advice.
WBC	< 3.5 x 10 ⁹ /L	Withold and seek Specialist advice,
Neutrophils	< 2.0 x 10 ⁹ /L	repeat FBC in 1 or 2 weeks.
Platelets	< 150 x 10 ⁹ /L or bleeding	
Significant deterioration in	Creatinine >30% of	Seek Specialist advice.
renal function	baseline.	Caution: dose reduction advised in renal impairment
Elevation in liver enzymes (or	>2 fold rise in AST, ALT	
falling albumin)	or Alk Phos (from upper	
	limit of reference range).	Withold and seek Specialist advice.
Serial decrease in WBC and/or	E.g. 6.0→5.0→4.5 over	
platelets within normal range	3 occasions	

Tips

- Prescribe within your competency
- Seek advice and support when unsure
- Identify resources
- Sign up to CAS alerts
- Be aware of care transition
- Document accurately
- Inform patients of monitoring requirements
- Set up follow up plan & automate recalls
- Review medicine doses/needs at every opportunity
- Regular audits

SPS Medicine Monitoring https://www.sps.nhs.uk/home/guidance/drug-monitoring/



Conclusion

- Medicine monitoring is vital part of patient journey
- It's a continues review of benefit Vs risk
- Involve patients in the monitoring process
- Set up process to automate monitoring